Concern for azotemia with angiotensin-converting enzyme inhibitors: Public health implications and clinical relevance

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages 801-803

  Bart, B A ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FUNCTION; PRIORITY JOURNAL; PUBLIC HEALTH; UREMIA;

EID: 0032716182     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70001-3     Document Type: Editorial

References (35)

1. Heart failure: management of patients with left-ventricular systolic dysfunction. Agency for Health Care Policy and Research. Clinical practice guideline: quick reference guide for clinicians. Rockville (MD): AHCPR; 1994. p. 1-25.
2. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
3. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
4. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997;18:736-53.
5. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995;274:462]. JAMA 1995;273:1450-6.
6. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. SEOSI Investigators. Eur Heart J 1997;18:1457-64.
7. Hillis GS, Trent RJ, Winton P, MacLeod AM, Jennings KP. Angiotensin-converting enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? QJM 1996;89:145-50.
8. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med 1997;157:1103-8.
9. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol 1997;79:581-6.
10. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20.
11. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. Eur Heart J. In press.
12. Forman DE, Chander RB, Lapane KL, Shah P, Stoukides J. Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure. J Am Ger Soc 1998;46:1550-4.
13. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998;19:L15-21.
14. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 1999;138:849-855.
15. Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992;152:704-10.
16. Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Sem Nephrol 1997;17:67-76.
17. Kostis JB, Shelton BJ, Yusuf S, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994;128:358-64.
18. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
19. Kostis JB, Shelton B, Gosselin G, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996;131:350-5.
20. Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ 1999;318:234-7.
21. MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998;352:13-6.
22. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
23. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5.
24. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
25. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984;3:1035-43.
26. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-44.
27. Henning R, Karlberg BE, Odar-Cederlof I, et al. Timolol and hydrochlorothiazide-amiloride in primary hypertension. Clin Pharmacol Ther 1980;28:707-14.
28. Holmer SR, Hense HW, Danser AH, Mayer B, Riegger GA, Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart 1998;80:45-8.
29. Hillis GS, Al-Mohammad A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996;76:427-9.
30. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995;26:1417-23.
31. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
32. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997;30:1417-9.
33. Krumholz HM. Time to focus on the more typical heart-failure patients. Lancet 1998;352:3-4.
34. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.
35. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J1986;62:179-82.